You may have been told you have NAFLD, then encounter MASLD in a newer article. Another report might mention NASH or MASH.
The changing names can make it seem as though you have developed a different condition.
MASLD is the newer term for metabolic dysfunction-associated steatotic liver disease. MASH describes its inflammatory form, with liver-cell injury. The distinction matters more than memorizing the abbreviations.
This guide explains the terms and what to clarify with your clinician.
Considering an additional educational resource? View the Fatty Liver Solution program and review its contents and claims. A paid guide cannot determine whether you have MASH or fibrosis.
Affiliate disclosure: This article contains affiliate links. We may earn a commission if you purchase through them, at no additional cost to you.
The Names at a Glance
| Term | Full name | Main distinction |
|---|---|---|
| NAFLD | Nonalcoholic fatty liver disease | Older terminology emphasizing liver fat without significant alcohol exposure |
| MASLD | Metabolic dysfunction-associated steatotic liver disease | Newer terminology emphasizing metabolic dysfunction |
| NASH | Nonalcoholic steatohepatitis | Older term for inflammation and liver-cell injury with fat |
| MASH | Metabolic dysfunction-associated steatohepatitis | Newer term for the inflammatory form of MASLD |
The definitions overlap substantially, but they are not simply identical labels in every clinical circumstance. Ask which diagnosis applies to your findings.
What Is MASLD?
MASLD describes liver fat associated with metabolic dysfunction. The definition includes at least one specified cardiometabolic risk factor.
Relevant factors include abnormal glucose regulation, blood pressure, blood fats or measures of excess body weight.
The wider diagnosis also considers alcohol and other explanations for liver fat.
Our fatty liver causes guide explains the risk discussion.
What Is MASH?
MASH involves inflammation and liver-cell injury in addition to liver fat.
It can occur with different amounts of fibrosis. Having MASH does not automatically mean you have cirrhosis.
Ask what evidence supports the diagnosis and whether scarring has been assessed.
Our fatty liver stages and fibrosis guide explains those separate findings.
Why Did the Terminology Change?
The newer naming system emphasizes metabolic dysfunction and uses “steatotic liver disease” as a broader framework.
Older terms remain common in research, medical records and product names. You may therefore see both naming systems while reading about the same general topic.
A change in wording alone does not establish that your condition improved or worsened.
Does Every Person With Liver Fat Have MASLD?
No. Liver fat can have other explanations.
NIDDK identifies alcohol, certain medicines, malnutrition and some rare conditions among possible causes. Alcohol-related and metabolic contributors can also overlap.
Do not choose the diagnosis from an ultrasound phrase alone. Your clinician should interpret it alongside your history and metabolic findings.
For the broader process, read our fatty liver diagnosis guide.
Can Ultrasound Tell MASLD From MASH?
Routine ultrasound can identify changes suggesting liver fat. It does not reliably establish the inflammation and injury that define steatohepatitis.
Further assessment may be appropriate depending on the clinical situation. A biopsy is used in selected cases.
Our fatty liver ultrasound guide explains the scan’s role and limitations.
Where Does Fibrosis Fit?
Fibrosis means liver scarring.
The name MASH describes inflammation and injury; the fibrosis stage describes the amount of scarring. Both can affect clinical decisions.
| Question | What it asks |
|---|---|
| Is liver fat present? | Whether steatosis has been identified |
| Is there steatohepatitis? | Whether inflammation and injury are present |
| Is there fibrosis? | Whether scarring has developed |
| How advanced is the fibrosis? | The severity of scarring |
Do not treat these as interchangeable results.
Looking for optional reading alongside your care? Review the Fatty Liver Solution program information. Compare its terminology and treatment claims with current medical guidance.
Why Does the Difference Affect Treatment?
Your diagnosis and fibrosis assessment help determine which management options are appropriate.
Diet, activity and treatment of associated conditions remain relevant. Selected adults with MASH and moderate-to-advanced fibrosis may also qualify for specific approved medicines.
The words “fatty liver” on a scan do not establish medication eligibility.
Our fatty liver medicines guide explains approved options and limitations.
Does MASH Always Progress to Cirrhosis?
No. A possible progression pathway is not a prediction for every person.
Ask your clinician about your findings, risk and monitoring plan. Avoid assuming that the abbreviation alone determines your future.
The useful next step is an individualized assessment and a clear care plan.
What If Your Records Still Say NAFLD or NASH?
Bring the report to your appointment and ask whether newer terminology applies.
Useful questions include:
- “Does MASLD describe my current diagnosis?”
- “Has MASH been established, or are we still assessing it?”
- “Do I have evidence of fibrosis?”
- “Does the wording change anything about my care?”
There is no need to rewrite your own diagnosis without clinical advice.
Can You Have MASLD at a Normal Weight?
Yes. Normal weight does not rule out metabolic dysfunction or liver fat.
Ask whether your findings fit the definition and whether other causes need consideration. Do not automatically adopt a weight-loss target intended for someone with obesity.
Our lean fatty liver guide explains the individualized approach.
How Should Progress Be Discussed?
Use specific outcomes rather than saying only “the MASLD is better.”
Ask whether there has been a change in liver fat, blood results, inflammation or fibrosis risk—and how that conclusion was reached.
Our signs fatty liver is improving guide explains why one favorable finding does not establish every outcome.
Questions for Your Next Appointment
Consider asking:
- “Which diagnosis fits my findings?”
- “What supports the diagnosis?”
- “Has fibrosis been assessed?”
- “Do I need further testing?”
- “Which treatments are appropriate?”
- “What will we monitor next?”
Bring complete reports rather than isolated abbreviations.
Frequently Asked Questions
Is MASLD just another word for MASH?
No. MASH is the inflammatory form of MASLD.
Is MASH the same as cirrhosis?
No. Cirrhosis describes advanced scarring.
Does a new name mean my condition worsened?
Not by itself. Ask what the clinical findings show.
Does ultrasound establish MASH?
Routine ultrasound does not reliably establish steatohepatitis.
Should an older program name worry me?
Older terminology alone does not establish quality. Evaluate the actual contents, evidence and current medical claims.
Focus on What the Diagnosis Means
Clarify whether your assessment concerns liver fat, inflammation, fibrosis or a combination.
Then agree on the next step through your fatty liver treatment plan. Understanding the findings is more useful than memorizing every abbreviation.
Interested in the optional paid resource? Visit the Fatty Liver Solution information page. Review its claims and purchase terms carefully; it cannot determine your diagnosis or guarantee recovery.
Resources
- AASLD: Steatotic Liver Disease Overview
- AASLD: MASLD Guidance and Nomenclature Resources
- NIDDK: Definition and Facts
- NIDDK: Diagnosis
Medical disclaimer: This article provides general educational information and does not replace individualized diagnosis, staging or treatment.